Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study

This study investigated the feasibility, safety, and potential benefit in motor symptom control when switching from a dopamine agonist to tolcapone as an adjunctive therapy in patients with Parkinson's disease with a fluctuating response to levodopa (l-dopa). We determined the efficacy of 2 rep...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical neuropharmacology 2010-05, Vol.33 (3), p.142-150
Hauptverfasser:	Ries, Vincent, Selzer, Roland, Eichhorn, Tobias, Oertel, Wolfgang H, Eggert, Karla
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Ambulatory Care Facilities Aromatic Amino Acid Decarboxylase Inhibitors Benserazide - adverse effects Benserazide - therapeutic use Benzophenones - adverse effects Benzophenones - therapeutic use Carbidopa - adverse effects Carbidopa - therapeutic use Catechol O-Methyltransferase Inhibitors Dopamine Agonists - adverse effects Dopamine Agonists - therapeutic use Drug Combinations Drug Therapy, Combination - adverse effects Dyskinesias - drug therapy Enzyme Inhibitors - adverse effects Enzyme Inhibitors - therapeutic use Feasibility Studies Female Humans Levodopa - adverse effects Levodopa - therapeutic use Male Middle Aged Nitrophenols - adverse effects Nitrophenols - therapeutic use Parkinson Disease - drug therapy Severity of Illness Index Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!